Hikma Pharmaceuticals PLC
LSE:HIK
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 722.5
2 083
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HIK stock under the Base Case scenario is 3 725.25 GBX. Compared to the current market price of 1 950 GBX, Hikma Pharmaceuticals PLC is Undervalued by 48%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Hikma Pharmaceuticals PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HIK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Hikma Pharmaceuticals PLC
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Hikma Pharmaceuticals PLC
Balance Sheet Decomposition
Hikma Pharmaceuticals PLC
Current Assets | 2.3B |
Cash & Short-Term Investments | 260m |
Receivables | 965m |
Other Current Assets | 1.1B |
Non-Current Assets | 2.6B |
Long-Term Investments | 63m |
PP&E | 1.1B |
Intangibles | 1.1B |
Other Non-Current Assets | 268m |
Current Liabilities | 1.4B |
Accounts Payable | 541m |
Short-Term Debt | 79m |
Other Current Liabilities | 760m |
Non-Current Liabilities | 1.2B |
Long-Term Debt | 1.1B |
Other Non-Current Liabilities | 120m |
Earnings Waterfall
Hikma Pharmaceuticals PLC
Revenue
|
3B
USD
|
Cost of Revenue
|
-1.6B
USD
|
Gross Profit
|
1.4B
USD
|
Operating Expenses
|
-813m
USD
|
Operating Income
|
617m
USD
|
Other Expenses
|
-332m
USD
|
Net Income
|
285m
USD
|
Free Cash Flow Analysis
Hikma Pharmaceuticals PLC
USD | |
Free Cash Flow | USD |
Hikma Pharmaceuticals reported robust performance across all divisions. Injectables showed significant growth, despite additional costs, with successful launches of unique 505(b)(2) products. Europe and MENA regions performed exceedingly well, with MENA overcoming currency challenges in Egypt and Sudan to achieve nearly 17% growth. Oncology tenders contributed to high profitability, and despite a mixed drug pricing environment, volumes increased leading to an uptick in demand. The company is optimistic, as FDA inspections of competitors may result in further market opportunities. Hikma's cash flow remains strong and the company is well-poised for future success.
What is Earnings Call?
HIK Profitability Score
Profitability Due Diligence
Hikma Pharmaceuticals PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Hikma Pharmaceuticals PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
HIK Solvency Score
Solvency Due Diligence
Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HIK Price Targets Summary
Hikma Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for HIK is 2 331.21 GBX with a low forecast of 2 020 GBX and a high forecast of 2 887.5 GBX.
Dividends
Current shareholder yield for HIK is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. The company also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
Officers
The intrinsic value of one HIK stock under the Base Case scenario is 3 725.25 GBX.
Compared to the current market price of 1 950 GBX, Hikma Pharmaceuticals PLC is Undervalued by 48%.